Cargando…
Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer
Most breast cancers are hormone receptor-positive, and tamoxifen is the mainstay of endocrine therapy for such patients. However, with the introduction of aromatase inhibitors and then fulvestrant, tamoxifen became a less preferred drug, even in a premenopausal setting. Many new approaches to tackle...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065093/ https://www.ncbi.nlm.nih.gov/pubmed/33907637 http://dx.doi.org/10.7759/cureus.14088 |